Abstract:BACKGROUND Payers and purchasers in the United States seek to moderate drug prices and align them with the incremental clinical benefit offered by individual medications; some policymakers have proposed linking U.S. prices to an index of prices paid in other nations. The German health care system resembles that of the United States in featuring multiple private payers but differs in featuring a highly coordinated process of comparative clinical assessment and price negotiations for drugs. OBJECTIVES To (a) measure trends in prices paid for physician-administered drugs in Germany before and after the mandate for comparative effectiveness assessment and price negotiations in 2011 and (b) compare them with price trends for the same drugs in the United States. METHODS This study observed trends in the prices paid for 80 physician-administered drugs, which account for approximately half of Medicare Part B drug spending. Quarterly data covering 2004-2018 were obtained for Germany from the Lauer-Taxe database, which contains net prices paid by all German payers. U.S. data were obtained from the Centers for Medicare & Medicaid Services, which publishes net prices paid by private U.S. payers and the Medicare Part B program. These data contain the net prices actually paid after accounting for all discounts and rebates, not merely the manufacturer's list price. Statistical analyses were conducted with multivariable difference-in-differences regression methods. RESULTS Before implementation in Germany of comparative effectiveness analysis and collective price negotiations, net U.S. prices for physician-administered drugs averaged 29.2% higher (95% CI = 26.6%-31.7) than those in Germany. After implementation of comparative effectiveness assessments and price negotiations in 2011, the divergence between U.S. and German prices increased another 28.9% (95% CI = 23.7%-34.3%). CONCLUSIONS Commercial health insurers and Medicare pay significantly higher net prices for physician-administered drugs than do insurers in Germany, with the divergence growing after the mandate in Germany that new drugs be subject to comparative effectiveness assessment and collective price negotiations. The experience of Germany may be of special value for the current U.S. debate over pharmaceutical pricing reform, given the demographic, economic, and health system similarities between the 2 nations. DISCLOSURES This study was supported by the Commonwealth Fund, New York. The sponsor had no role in the study design, conduct, interpretation, or writing up of results. Whaley reports a grant from the National Institute on Aging, unrelated to this work. The other authors have no potential conflicts of interest to report.

S1989 A Global Comparison of Liver Transplant Drug Pricing: US vs the G7 Countries and Australia

S1990 A Global Comparison of Hepatitis B Drug Pricing: US vs the Other G7 Countries and Australia

A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

International Prescription Drug Price Comparisons: Estimates Using 2022 Data

The economic implications of broader sharing of liver allografts

The rising cost of liver transplantation in the United States

International Comparison of Drug Price Level in China

Liver Transplant Costs and Activity After United Network for Organ Sharing Allocation Policy Changes

Financial Impact of Liver Sharing and Organ Procurement Organizations' Experience With Share 35: Implications for National Broader Sharing

Identifying drivers of cost in pediatric Liver Transplantation

Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland

Assessing the cost-effectiveness of replacing antimetabolites with mTOR inhibitors in heart transplant immunosuppression in China: a network meta-analysis-based economic evaluation

Influence of Preoperative Status on the Cost of Liver Transplantation

The adoption of generic immunosuppressant medications in kidney, liver, and heart transplantation among recipients in Colorado or nationally with Medicare part D

Current Burden of and Geographic Disparities in Liver Mortality and Access to Liver Transplant

Increasing Divergence in Drug Prices Between the United States and Germany After Implementation of Comparative Effectiveness Analysis and Collective Price Negotiations.

Healthcare costs in renal transplant recipients using branded versus generic ciclosporin

The Medical Costs of Determining Eligibility and Waiting for a Kidney Transplantation

Surgical treatment of liver cancer and pancreatic cancer under the China Healthcare Security Diagnosis Related Groups payment system

Cost Analysis and Determinants of Living Donor Liver Transplantation in Taiwan

Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19